What should I know about arterial thromboembolic events (ATEs)?
Arterial thromboembolic events occurred at a higher incidence in patients receiving Avastin with chemotherapy (4.4%) vs chemotherapy alone (1.9%); less than 1% of events were fatal. There was a correlation between age (65 years and older) and increased risk. Avastin should be permanently discontinued in patients who experience a severe AT event while on treatment. The safety of resuming Avastin therapy after resolution of an AT event has not been studied.
